News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Banyu Pharmaceutical Co. And Ono Pharmaceutical Company, Ltd. Begins Phase III Clinical Trials Of A DPP-4 Inhibitor For Type 2 Diabetes Patients
August 14, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Banyu Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. will begin Phase III Clinical Trial of Sitagliptin (Development Code: MK-0431/ONO-5435) in Japan.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Asia
MORE ON THIS TOPIC
FDA
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
July 27, 2026
·
3 min read
·
Heather McKenzie
Neuroscience
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
July 27, 2026
·
2 min read
·
Michael Gibney
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
·
3 min read
·
Gabrielle Masson
Insights
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
July 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
